Propellon Therapeutics, a Toronto, Canada-based developer of a portfolio of WDR5-targeted anti-cancer therapeutics, raised $3.0M in seed financing.
Fight Against Cancer Innovation Trust (FACIT), which has established Propellon’s WDR5 inhibitor platform, made the investment in the company.
The company will use the funds to accelerate the nomination of a candidate drug and to ask for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.
Led by Dr. David O’Neill, President, Propellon is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification.
The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival.
FinSMEs
22/03/2017